Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration
Shots:
- The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg- q4w) vs aflibercept (2 mg- q4w) following the loading phase in patients with wet AMD who have persistent retinal fluid despite anti-VEGF therapy
- Results: met its 1EPs i.e. non-inferiority in mean change in BCVA from baseline and superiority on 2EPs @ 1 yrs. Beovu (6mg- q4w) was associated with higher rates of IOI (9.3% vs 4.5%) which includes RV (0.8% vs 0.0%) & RO (2.0% vs 0.0%)- overall rate of vision (4.8% vs 1.7%)
- Novartis has decided on early termination of the RAPTOR & RAVEN studies- which assessed the efficacy & safety of Beovu in RVO- and included 6 initial monthly injections
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com